Royal Bank Of Canada Issues Positive Forecast for GRAIL (NASDAQ:GRAL) Stock Price

GRAIL (NASDAQ:GRAL) had its target price raised by Royal Bank Of Canada from $84.00 to $100.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “sector perform” rating on the stock. Royal Bank Of Canada‘s target price would suggest a potential downside of 16.20% from the company’s previous close.

GRAL has been the topic of a number of other reports. Morgan Stanley boosted their target price on shares of GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. Robert W. Baird lifted their price target on shares of GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday, September 22nd. TD Cowen boosted their price objective on shares of GRAIL from $88.00 to $180.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Finally, Canaccord Genuity Group increased their price objective on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 28th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, GRAIL has a consensus rating of “Hold” and an average price target of $121.40.

GRAIL Price Performance

GRAL stock traded down $24.32 during midday trading on Thursday, reaching $119.34. 1,407,085 shares of the stock were exchanged, compared to its average volume of 976,080. GRAIL has a 52 week low of $41.50 and a 52 week high of $166.48. The company has a fifty day moving average price of $115.58 and a 200 day moving average price of $79.12. The stock has a market capitalization of $5.33 billion, a PE ratio of -12.16 and a beta of 2.86.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($2.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.45) by $0.24. The company had revenue of $37.53 million during the quarter, compared to the consensus estimate of $44.21 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. As a group, analysts anticipate that GRAIL will post -10.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Andrew Partridge sold 7,873 shares of the company’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $1,152,528.47. Following the sale, the insider directly owned 155,865 shares in the company, valued at $22,817,077.35. This represents a 4.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Aaron Freidin sold 23,619 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $146.39, for a total transaction of $3,457,585.41. Following the sale, the chief financial officer directly owned 225,364 shares of the company’s stock, valued at $32,991,035.96. This represents a 9.49% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 129,944 shares of company stock valued at $14,832,805 over the last ninety days. 1.83% of the stock is owned by company insiders.

Hedge Funds Weigh In On GRAIL

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its stake in GRAIL by 29.0% during the first quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock worth $47,241,000 after purchasing an additional 205,611 shares during the period. Russell Investments Group Ltd. increased its holdings in GRAIL by 255.6% in the second quarter. Russell Investments Group Ltd. now owns 28,403 shares of the company’s stock worth $1,939,000 after purchasing an additional 20,416 shares in the last quarter. State Street Corp lifted its stake in GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after buying an additional 493,621 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in GRAIL in the second quarter valued at approximately $1,171,000. Finally, BlackRock Inc. boosted its holdings in shares of GRAIL by 20.5% during the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock worth $244,207,000 after buying an additional 608,539 shares in the last quarter.

GRAIL News Roundup

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: An FDA advisory committee voted in favor of approving GRAIL’s Galleri multi-cancer early detection test. The vote is supportive, though the FDA’s final decision is still pending; management expects a decision in early 2027. GRAIL Q3 results and FDA update
• Positive Sentiment: Galleri test volume rose about 24% year over year to more than 56,000 in the quarter, while revenue increased 14% to $37.3 million. These figures show continued commercial growth. GRAIL Q3 results
• Neutral Sentiment: GRAIL’s adjusted quarterly loss per share was narrower than analysts expected. RBC also raised its price target to $100 from $84 but kept its Sector Perform rating, signaling a measured view of the shares. RBC price target update
• Negative Sentiment: Quarterly revenue of about $37.5 million fell short of the roughly $44.2 million analyst estimate, disappointing investors despite the EPS beat. The miss has been associated with pressure on the stock. GRAIL revenue miss coverage
• Negative Sentiment: GRAIL is cutting Galleri prices to encourage adoption ahead of the FDA decision. The strategy could support test volumes, but may weigh on revenue growth and margins as the company works to scale sales. GRAIL earnings call takeaways

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.